Published on: 2025-05-19 07:32:12
The Hims app arranged on a smartphone in New York on Feb. 12, 2025. Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly 's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, through its platform. Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss progra
Keywords: compounded hims loss medications weight
Find related items on AmazonPublished on: 2025-05-22 19:15:09
Image by Futurism You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized men's health app also offers hair loss treatment, STD meds, mental health services and GLP-1 weight loss treatments — though that's now going away. Fueled by global demand and slow production, 2024 was the year of the GLP-1 shortage. Originally used to treat type 2 diabetes, GLP-1 ag
Keywords: 1s compounded fda glp hims
Find related items on AmazonPublished on: 2025-07-15 11:00:42
The Hims app arranged on a smartphone in New York on Feb. 12, 2025. Shares of Hims & Hers Health closed down 22% on Tuesday, a day after the telehealth company released fourth-quarter results that disappointed on gross margin and sparked concerns about the future of its weight loss business. Hims & Hers reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year. Net income climbed to $26.01 million, or 11 cents per share, from $1.25 million, o
Keywords: analysts company hims loss said
Find related items on AmazonPublished on: 2025-07-15 06:56:56
The Hims app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. Shares of Hims & Hers Health fell 28% on Tuesday, a day after the telehealth company released fourth-quarter results that disappointed on gross margin and sparked concerns about the future of its weight loss business. Hims & Hers reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year. Net income climbed to $26.01 million, or 11 cents per share, from $1.25 m
Keywords: analysts company hims loss said
Find related items on AmazonPublished on: 2025-07-14 17:51:52
The New York Stock Exchange with a Hims & Hers Health banner is pictured in the Manhattan borough of New York City. Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Here's how the company did, compared to analysts' consensus estimates from LSEG: Earnings per share: 11 cents vs. 10 cents expected 11 cents vs. 10 cents expected Revenue: $481 million vs
Keywords: company hims million revenue said
Find related items on AmazonPublished on: 2025-07-14 15:43:06
The New York Stock Exchange with a Hims & Hers Health banner is pictured in the Manhattan borough of New York City. Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Here's how the company did: Earnings per share: 11 cents vs. 10 cents expected by LSEG 11 cents vs. 10 cents expected by LSEG Revenue: $481 million vs. $470 million expected by LSEG Reve
Keywords: company health hims million revenue
Find related items on AmazonPublished on: 2025-07-12 03:02:43
Shares of Hims & Hers Health closed down around 26% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved. Semaglutide is the active ingredient in Novo Nordisk's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been
Keywords: compounded drugs hims medications semaglutide
Find related items on AmazonPublished on: 2025-07-12 05:56:39
Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved. Semaglutide is the active ingredient in Novo Nordisk's blockbuster weight loss drugs Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies like Hims & Hers have been pr
Keywords: company compounded friday hims semaglutide
Find related items on AmazonGo K’awiil is a project by nerdhub.co that curates technology news from a variety of trusted sources. We built this site because, although news aggregation is incredibly useful, many platforms are cluttered with intrusive ads and heavy JavaScript that can make mobile browsing a hassle. By hand-selecting our favorite tech news outlets, we’ve created a cleaner, more mobile-friendly experience.
Your privacy is important to us. Go K’awiil does not use analytics tools such as Facebook Pixel or Google Analytics. The only tracking occurs through affiliate links to amazon.com, which are tagged with our Amazon affiliate code, helping us earn a small commission.
We are not currently offering ad space. However, if you’re interested in advertising with us, please get in touch at [email protected] and we’ll be happy to review your submission.